Table 2 Laboratory indexes and clinical outcomes of young children with EV-A71 induced Severe HFMD
Outcomes | Picco(n = 8) | Control (n = 12) | p |
|---|---|---|---|
pH | 7.18 [7.05, 7.37] | 7.21 [7.07, 7.31] | 0.744 |
PaO2/FiO2, mmHg | 187 [152.5, 217.8] | 195 [161.5, 210] | 0.534 |
LAC, mmol/L | 3.23 [2.56, 4.74] | 3.43 [2.63,4.56] | 0.671 |
Cre, μmol/L | 55.0 [28.1, 79.8] | 58 [28.5, 75.5] | 0.791 |
TNI, μg/L | 0.15 [0.05, 0.38] | 0.13 [0.06, 0.40] | 0.797 |
CK-MB, IU/L | 28 [18, 54] | 25 [16, 59] | 0.749 |
Cases of vasoactive agents | |||
Sodium nitroprusside | 2 | 3 | 0.999 |
Urapidil hydrochloride | 5 | 8 | 0.848 |
Dopamine | 2 | 1 | 0.306 |
Norepinephrine | 3 | 4 | 0.848 |
Days of vasoactive drugs usage | 7.5 [6.0, 10.0] | 7.8 [6.3,9.5] | 0.714 |
Cases of AKI | 3 | 5 | 0.852 |
Cases of MV | 4 | 5 | 0.714 |
Cases of fluid overload | 1 | 6 | 0.085 |
Length of ICU stay, days | 11 (9, 16) | 11.3 (9.3, 15.8) | 0.847 |
Duration of MV, days | 6.9 [4.7,8.8] | 9.3 [5.9, 12.7] | 0.028 |